van Dongen JJ - Search Results

1

Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR.

Boeckx N, Jansen MW, Haskovec C, Vandenberghe P, van der Velden VH, van Dongen JJ. Boeckx N, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2005 Jul;19(7):1292-5. doi: 10.1038/sj.leu.2403761. Leukemia. 2005. PMID: 15843824 No abstract available.

2

Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.

Boeckx N, Willemse MJ, Szczepanski T, van der Velden VH, Langerak AW, Vandekerckhove P, van Dongen JJ. Boeckx N, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2002 Mar;16(3):368-75. doi: 10.1038/sj.leu.2402387. Leukemia. 2002. PMID: 11896540

3

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.

van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2002 May;16(5):928-36. doi: 10.1038/sj.leu.2402475. Leukemia. 2002. PMID: 11986956

4

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.

van der Velden VH, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Jul;16(7):1372-80. doi: 10.1038/sj.leu.2402515. Leukemia. 2002. PMID: 12094263

5

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2003 Jun;17(6):1013-34. doi: 10.1038/sj.leu.2402922. Leukemia. 2003. PMID: 12764363 Review.

6

Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program.

van der Velden VH, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T, Gottardi E, Pallisgaard N, Beillard E, Hop WC, Hoogeveen PG, Gabert J, van Dongen JJ; Europe Against Cancer Program. van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2004 Apr;18(4):884-6. doi: 10.1038/sj.leu.2403309. Leukemia. 2004. PMID: 14961029 Free article. No abstract available.

7

Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler.

Jansen MW, van der Velden VH, van Dongen JJ. Jansen MW, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2005 Nov;19(11):2016-8. doi: 10.1038/sj.leu.2403939. Leukemia. 2005. PMID: 16151462 No abstract available.

8

Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR.

Boeckx N, De Roover J, van der Velden VH, Maertens J, Uyttebroeck A, Vandenberghe P, van Dongen JJ. Boeckx N, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2005 Nov;19(11):1988-90. doi: 10.1038/sj.leu.2403961. Leukemia. 2005. PMID: 16193088 Clinical Trial. No abstract available.

9

Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.

Jansen MW, Corral L, van der Velden VH, Panzer-Grümayer R, Schrappe M, Schrauder A, Marschalek R, Meyer C, den Boer ML, Hop WJ, Valsecchi MG, Basso G, Biondi A, Pieters R, van Dongen JJ. Jansen MW, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2007 Apr;21(4):633-41. doi: 10.1038/sj.leu.2404578. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268512

10

Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring.

van der Velden VH, Wijkhuijs JM, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2008 Mar;22(3):641-4. doi: 10.1038/sj.leu.2404925. Epub 2007 Sep 13. Leukemia. 2008. PMID: 17851557 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

590 results

Search Page

Filters